CFA
BCRX icon

Carroll Financial Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Carroll Financial Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$4K Hold
294
– – ﹤0.01% 1368
2021
Q3 		$4K Hold
294
– – ﹤0.01% 1398
2021
Q2 		$4K Hold
294
– – ﹤0.01% 1465
2021
Q1 		$2K Buy
+294
New +$3.03K ﹤0.01% 1482

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Carroll Financial Associates's BCRX Position: Q4 2021 in Review

Carroll Financial Associates held its BioCryst Pharmaceuticals (BCRX) position steady in Q4 2021 at 294 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

Carroll Financial Associates first reported a position in BCRX in Q1 2021 and has held it in 4 quarters since. 206 funds tracked by Wall St. Rank hold BCRX as of Q4 2021.

  • Carroll Financial Associates held 294 shares of BioCryst Pharmaceuticals worth $4K as of Q4 2021.
  • Carroll Financial Associates left its BioCryst Pharmaceuticals share count unchanged in Q4 2021.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1368 holding.
  • Carroll Financial Associates first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 4 quarters since.
  • 206 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.